Harvard Management CO Inc Kinnate Biopharma Inc. Transaction History

Harvard Management CO Inc

  • $1.73 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
SELL
$2.33 - $6.84 $82,908 - $243,387
-35,583 Reduced 7.15%
462,418 $1.4 Million
Q4 2020

Feb 12, 2021
BUY
$36.35 - $45.25 $18.1 Million - $22.5 Million
498,001 New
498,001 $19.8 Million

Others Institutions Holding KNTE

# of Institutions
2
Shares Held
292K
Call Options Held
0
Put Options Held
0
View Full List

About Kinnate Biopharma Inc.

KNTE Quotes by TradingView
  • Ticker KNTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,145,600
  • Description
  • Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...
More about KNTE
Track This Portfolio

Track Harvard Management CO Inc Portfolio

Follow Harvard Management CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harvard Management CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Harvard Management CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email